| Antifibrotic activity of an inhibitor of histone deacetylases in DOCA‐salt hypertensive rats A Iyer, A Fenning, J Lim, GT Le, RC Reid, MA Halili, DP Fairlie, L Brown British journal of pharmacology 159 (7), 1408-1417, 2010 | 155 | 2010 |
| C5aR and C3aR antagonists each inhibit diet‐induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling J Lim, A Iyer, JY Suen, V Seow, RC Reid, L Brown, DP Fairlie The FASEB Journal 27 (2), 822-831, 2013 | 147 | 2013 |
| Diet‐induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism J Lim, A Iyer, L Liu, JY Suen, RJ Lohman, V Seow, MK Yau, L Brown, ... The FASEB Journal 27 (12), 4757-4767, 2013 | 128 | 2013 |
| Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a V Seow, J Lim, A Iyer, JY Suen, JK Ariffin, DM Hohenhaus, MJ Sweet, ... The Journal of Immunology 191 (8), 4308-4316, 2013 | 100 | 2013 |
| Pathway‐selective antagonism of proteinase activated receptor 2 JY Suen, A Cotterell, RJ Lohman, J Lim, A Han, MK Yau, L Liu, ... British journal of pharmacology 171 (17), 4112-4124, 2014 | 75 | 2014 |
| An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats A Iyer, J Lim, H Poudyal, RC Reid, JY Suen, J Webster, JB Prins, ... Diabetes 61 (9), 2320-2329, 2012 | 61 | 2012 |
| A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells Y Jiang, MK Yau, J Lim, KC Wu, W Xu, JY Suen, DP Fairlie Journal of Pharmacology and Experimental Therapeutics 364 (2), 246-257, 2018 | 60 | 2018 |
| Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amides RC Reid, MK Yau, R Singh, J Lim, DP Fairlie Journal of the American Chemical Society 136 (34), 11914-11917, 2014 | 60 | 2014 |
| Bicyclic helical peptides as dual inhibitors selective for Bcl2A1 and Mcl-1 proteins A D. de Araujo, J Lim, KC Wu, Y Xiang, AC Good, R Skerlj, DP Fairlie Journal of medicinal chemistry 61 (7), 2962-2972, 2018 | 46 | 2018 |
| Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists V Seow, J Lim, AJ Cotterell, MK Yau, W Xu, RJ Lohman, WM Kok, ... Scientific Reports 6, 2016 | 45 | 2016 |
| Biased signaling by agonists of protease activated receptor 2 Y Jiang, MK Yau, WM Kok, J Lim, KC Wu, L Liu, TA Hill, JY Suen, ... ACS chemical biology 12 (5), 1217-1226, 2017 | 44 | 2017 |
| Protease activated receptor 2 (PAR2) modulators: a patent review (2010–2015) MK Yau, J Lim, L Liu, DP Fairlie Expert opinion on therapeutic patents 26 (4), 471-483, 2016 | 38 | 2016 |
| Downsizing a human inflammatory protein to a small molecule with equal potency and functionality RC Reid, MK Yau, R Singh, JK Hamidon, AN Reed, P Chu, JY Suen, ... Nature communications 4 (1), 2802, 2013 | 38 | 2013 |
| Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a RJ Lohman, JK Hamidon, RC Reid, JA Rowley, MK Yau, MA Halili, ... Nature communications 8 (1), 351, 2017 | 36 | 2017 |
| Potent heterocyclic ligands for human complement C3a receptor RC Reid, MK Yau, R Singh, JK Hamidon, J Lim, MJ Stoermer, DP Fairlie Journal of Medicinal Chemistry 57 (20), 8459-8470, 2014 | 29 | 2014 |
| Electrophilic helical peptides that bond covalently, irreversibly, and selectively in a protein–protein interaction site AD de Araujo, J Lim, AC Good, RT Skerlj, DP Fairlie ACS Medicinal Chemistry Letters 8 (1), 22-26, 2017 | 26 | 2017 |
| Potent small agonists of protease activated receptor 2 MK Yau, JY Suen, W Xu, J Lim, L Liu, MN Adams, Y He, JD Hooper, ... ACS medicinal chemistry letters 7 (1), 105-110, 2016 | 26 | 2016 |
| PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR Y Jiang, J Lim, KC Wu, W Xu, JY Suen, DP Fairlie British Journal of Pharmacology 178 (4), 913-932, 2021 | 24 | 2021 |
| Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition AJ Kennedy, L Sundström, S Geschwindner, EKY Poon, Y Jiang, R Chen, ... Communications biology 3 (1), 782, 2020 | 24 | 2020 |
| Achiral derivatives of hydroxamate AR-42 potently inhibit class I HDAC enzymes and cancer cell proliferation J Tng, J Lim, KC Wu, AJ Lucke, W Xu, RC Reid, DP Fairlie Journal of medicinal chemistry 63 (11), 5956-5971, 2020 | 21 | 2020 |
David P FairlieProfessor, University of QueenslandVerified email at imb.uq.edu.au
